Abstract
Many factors regulate cancer cell apoptosis, among which Survivin has a strong anti-apoptotic effect and PHLPP is a tumor suppressor gene that can induce significant apoptosis. However, the relationship between PHLPP and Survivin in gallbladder carcinoma (GBC) has not been reported. This study found that PHLPP expression is decreased and Survivin expression is increased in GBC tissues and cell lines. Their expression levels showed an inverse relationship and were associated with poor prognosis of GBC patients. Loss of PHLPP can increase the level of phosphorylated Survivin and induce the nuclear export of Survivin, which thus inhibit cell apoptosis and promote cell proliferation in GBC cells. The process that PHLPP regulates Survivin phosphorylation and intracellular localization is involved in AKT activity. Re-overexpression of PHLPP in GBC cells can decrease AKT phosphorylation level. Reduced expression of PHLPP in GBC is associated with high expression of miR-495. Increasing PHLPP expression or inhibiting miR-495 expression can induce apoptosis and suppress tumor growth in GBC xenograft model in nude mice. The results revealed the role and mechanism of PHLPP and Survivin in GBC cells and proposed strategies for gene therapies targeting the miR-495 / PHLPP / AKT / Survivin regulatory pathway.
Highlights
Inhibition of apoptosis is a main factor in the uncontrolled proliferation of cancer cells and is closely related to the tumorigenesis and progression of malignant tumors
The results showed that 30.51% (18/59) of gallbladder carcinoma (GBC) tissues were positive for PH domain leucine-rich repeat protein phosphatase (PHLPP) and 76.27% (45/59) positive for Survivin
PHLPP was mainly expressed in cytoplasm of cancer cells, and Survivin was mainly expressed in cytoplasm and nuclei of cancer cells
Summary
Inhibition of apoptosis is a main factor in the uncontrolled proliferation of cancer cells and is closely related to the tumorigenesis and progression of malignant tumors. In most types of human tumors, such as breast, liver, lung, colorectal, pancreatic, stomach cancers and malignant melanoma, activation of extracellular signal regulated kinase (ERK) and phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT) signaling pathways induces changes in biological behaviors, such as malignant transformation, inhibition of apoptosis, increased activity of cell proliferation and metastasis These effects result in malignant progression of cancer and poor prognosis of patients [1,2,3]. Activation of the STAT3 signaling pathway can upregulate the target genes, including Bcl-X, Bcl-2, Cyclin D1, vascular endothelial growth factors (VEGF), Fas, Survivin and other factors, allowing cancer cells to escape apoptosis and inducing cell proliferation [5, 6]. The regulatory mechanism of Survivin overexpression in malignant tumors is not clear yet
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have